Myo-inositol and Melatonin in Pre-menopausal Women
- Conditions
- Pre-menopausal Irregular Cycles and Bleedings
- Interventions
- Dietary Supplement: melatonin plus myo-inositolDietary Supplement: myo-inositolDietary Supplement: melatonin
- Registration Number
- NCT01115127
- Lead Sponsor
- University of Messina
- Brief Summary
The purpose of this study is to determine whether myo-inositol and melatonin, or myo-inositol alone, or melatonin alone, are effective in normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.
- Detailed Description
Melatonin has produced a remarkable significant improvement of thyroid function, positive changes of gonadotropins towards reduced levels, and in some women a re-acquisition of normal menstrual cycle. Furthermore, an abrogation of menopause-related depression, amelioration of hot-flashes and improvement of quality and duration of sleep has been reported.
Myo-inositol is involved in several aspects of human reproduction. Elevated concentrations of myo-inositol in human follicular fluids appear to play a positive function in follicular maturity and provide a marker of good quality oocytes. Nevertheless its positive role in PCOS women is a consequence of a defect in the insulin signalling pathway (inositol-containing phosphoglycan mediators) that seems to be primarily implicated in the pathogenesis of insulin resistance
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 90
- all pre-menopausal women with irregular cycles and bleedings
- pre-menopausal women who take hormonal drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description melatonin plus myo-inositol melatonin plus myo-inositol 30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months myo-inositol myo-inositol 30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months. melatonin melatonin 30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
- Primary Outcome Measures
Name Time Method Normalizing irregular bleeding and anovulatory cycles in pre-menopausal women. 12 months
- Secondary Outcome Measures
Name Time Method Evaluation of metabolic markers (insulin, glucose, total cholesterol, HDL-cholesterol, triglycerides). 12 months Serum assays of thyroid hormones. 12 months Assays of gonadotropins and estradiol serum levels 12 months Variation of blood pressure. 12 months Variation of mood, hot flashes, quality of sleep. 12 months
Trial Locations
- Locations (1)
University Hospital
🇮🇹Messina, Italy